Study On Effects Of Simvastatin Combined With Ezetimibe On Proportions Of T Lymphocyte Subpopulations In Patient With Acute Myocardial Infarction

Objectives:To compare the effects of simvastatin combined with ezetimibe and simvastatin alone on proportions of peripheral blood CD4+CD28- and CD4+CD25+Fox P3+ regulatory T cells in patients with acute myocardial infarction(AMI) and explore the effects of simvastatin combined with ezetimibe in AMI. Methods:40 AMI patients that were hospitalized and treated in the intensive care unit of Shanxi Cardiovascular Hospital from April 2014 to November 2014 were selected and divided randomly into two groups: the control group and the experimental group; patients in the control group(n=20) were given 40 mg simvastatin once a day in the evening, while patients in the experimental group(n=20) were given 40 mg simvastatin once a day in the evening and 10 mg ezetimibe once a day. For all patients, proportions of peripheral blood CD4+CD28- and CD4+CD25+Fox P3+ T cells in CD4 + T cells were detected by flow cytometry before treatment and 15 days after treatment, respectively. Results:There was no statistical significance(P >0.05) regarding percentages of CD4+CD28-T cells in CD4+ T cells before treatment(95.41±5.24)% and 15 days after treatment(95.07±2.24)% in the control group, while for the experimental group, the percentage of CD4+CD28- T cells in CD4+ T cells 15 days after treatment(91.72±4.98) % decreased compared to that before treatment(93.55±6.43)%, with statistical significance(P<0.05); there was no statistical significance(P>0.05) regarding percentages of CD4+CD25+Fox P3+ T cells in CD4+ T cells before treatment(0.81±0.79)% and 15 days after treatment(0.86±0.86)% in the control group, and for the experimental group, there was no statistical significance(P>0.05) regarding percentages of CD4+CD25+Fox P3+ T cells in CD4+ T cells before treatment(0.85±0.87)% and 15 days after treatment(0.62±0.57)%. Conclusions:Due to immune effect cell disorders in patients with acute myocardial infarction leads to immune dysfunction,which involved in plaque instability; Application of simvastatin combined with ezetimibe in AMI patients can down-regulate peripheral blood CD4+CD28- T lymphocytes and compared with simvastatin alone may have additional benefits in reduce the incidence of acute thrombotic events.